AM

Affluent Medical

www.affluentmedical.com link_icon

Company Research Report: Affluent Medical



Company Overview



  • Name: Affluent Medical SA

  • Mission: Affluent Medical is committed to offering the best available therapies worldwide for largely unmet medical needs in terms of structural heart diseases and urological therapies. The company focuses on designing a new generation of minimally invasive prostheses with the aim of mimicking anatomy and restoring native physiology for critical functions.

  • Founded: Although the current form of the company was established in 2018, it emerged from the merger of three separate companies: Kephalios, Kardiozis, and MyoPowers, created from 2011 to 2014.

  • Key People:

  • Michel Therin: Chairman of the Board

  • Sébastien Ladet, Ph.D.: Chief Executive Officer

  • Christophe de Vregille: Chief Financial Officer

  • Dr. Christophe Giot, M.D.: Chief Medical Officer and Vice President Clinical Affairs

  • Claire André: Quality Director

  • Others: Benjamin Renault, Céline Buard, Prof. François Laborde, Olivier Belamy, Mélanie Cantal, Eric Jague

  • Headquarters: 320 Avenue Archimède, Les pléiades III Bâtiment B, 13100 Aix-en-Provence, France

  • Number of Employees: No information available

  • Revenue: No information available

  • Known For: Specializes in developing breakthrough medical devices focused on mitral valve repair, mitral valve replacement, and urinary incontinence treatment.


Products



Structural Heart



1. Kalios™
  • Purpose: Mitral valve repair

  • Description: The first mitral annuloplasty device that can be percutaneously adjusted post-implantation.

  • Key Features:

  • Reduces surgical procedures.

  • Anatomically based to restore critical functions.

  • Adjustments can be made post-operatively without further surgery.

  • Clinical testing ongoing since 2019.


2. Epygon
  • Purpose: Mitral valve replacement

  • Description: A "physiological" transcatheter mitral prosthesis designed to restore the natural blood flow vortex in the left ventricle.

  • Key Features:

  • Improves ventricular function.

  • Minimizes energy loss and heart risk.

  • Clinical testing started in 2022.


Urology



1. Artus
  • Purpose: Treatment of urinary incontinence

  • Description: A high-tech adjustable sphincter that is minimally invasive and user-friendly.

  • Key Features:

  • Patients can use a remote control for operation.

  • Personalizable settings based on patient lifestyle and condition changes.

  • Clinical testing includes success in first-in-human implantation as of March 2024.


Vascular



1. Kardiozis
  • Purpose: Treatment of abdominal aortic aneurysm

  • Description: A stent technology that prevents internal aneurysm circulation.

  • Key Features:

  • Minimally invasive surgical solution.

  • Uses thrombogenic fibers to promote thrombosis.

  • Clinical testing ongoing.


Recent Developments



  • Agreements and Financials:

  • Signed agreements for mitral valve technologies with a EUR 15M upfront payment in July 2024.

  • Successful first-in-human implantation of the Artus sphincter in March 2024.

  • Product Developments:

  • Clinical phases continue for Kalios™, Epygon, and Artus with large-scale testing planned in various European centers.

  • Positive performance at 1-year follow-up for Epygon's biomimetic valve.

  • Partnerships:

  • Collaborative synergies with prominent European hospitals and research centers.

  • Events and Conferences:

  • Participated in major conferences including PCR London Valves in November 2023 and several others in 2024 showcasing their technology and clinical trial advancements.


No other information is available for additional fields requested.



This report compiles available data into a structured format for professional analysis of Affluent Medical SA's market presence and operational focus.